Introduction: Despite available data from other Asian countries, the prevalence of epidermal growth factor receptor (EGFR) mutations among lung adenocarcinoma patients has not been reported in Malaysia. This study sought to determine the frequency of EGFR mutations among multiethnic Malaysian patients diagnosed with lung adenocarcinoma. Methods: Demographic and clinical information of patients whose lung adenocarcinoma biopsy specimens were submitted for EGFR mutation testing at Sime Darby Medical Center from 2009 to 2011 were analyzed. EGFR mutations at exons 18, 19, 20, and 21 were detected either through bidirectional sequencing or real-time polymerase chain reaction. Results: Among 812 patients in the study, 49% were female, 63.7% were ethnic Chinese, 29.4% Malay, 4.8% Indian, and 2.1% other ethnic groups. Mutations were present in the tumors of 321 patients (39.5%), with mutations at exons 19 (23.5%) and 21 (14.9%) being the most common. Mutations were significantly more frequent among women than in men (52.5% versus 27.8%, p < 0.001). Although mutations were more common among Chinese (40.8%) compared with Malay (37.2%) or Indian (33.3%) patients, the difference was not statistically significant (p = 0.591). Of 211 patients with smoking history records, never-smokers had a higher mutation rate compared with ever-smokers (54.8% versus 20.7%, p < 0.001). Conclusion: EGFR mutations were present in 39.5% of patients. Mutations were more common in women and never-smokers with no differences in mutation frequency between different ethnicities. Because of the high mutation rates, reflex testing for EGFR mutation should be a routine practice for advanced lung adenocarcinoma patients in Malaysia.
A denocarcinoma is the most common histologic subtype of non-small-cell lung cancer in many parts of the world. 1 Many studies have shown epidermal growth factor receptor (EGFR) mutations to be associated with improved response to treatment with EGFR tyrosine kinase inhibitors (TKIs). [2] [3] [4] EGFR TKIs such as gefitinib and erlotinib inhibit the EGFR signaling pathway by acting selectively through competitive inhibition of the binding of adenosine triphosphate to the tyrosine kinase domain of the receptor. 5 Lung cancer is the third most common cancer reported in Malaysia, with an incidence of 10.3 cases per 100,000 population in 2006, out of a total incidence rate of 109.8 cases of cancer per 100,000. 6 Adenocarcinoma is the most common lung cancer cell type among Malaysian men and women and in smokers and never-smokers. 7, 8 At diagnosis, the majority of patients have inoperable locally advanced or metastatic disease. 9 Malaysia has a multiethnic population comprising three major ethnic groups of Malays (54.6%), Chinese (24.6%), Indians (7.3%), and other ethnic minorities (13.5%). 10 Other studies have shown that higher frequencies of EGFR mutation in non-small-cell lung cancer are found among East Asians, women, never-smokers, and adenocarcinoma histologic subtype. 11, 12 Because lung adenocarcinoma patients with such demographic characteristics have also been reported to respond better to TKI treatment, information about the prevalence of EGFR mutation in different ethnic groups has important implications for treatment. 2, 13, 14 Similar findings have been reported in studies from China, [15] [16] [17] [18] Japan, 1, 19, 20 Taiwan, 1, 21 Australia, 1 and India. 22 However, apart from a single-center study conducted in Singapore, 23 little is known about the prevalence of EGFR mutation in the populations from South East Asia, and whether it is similar to other parts of Asia.
In Malaysia, EGFR mutation testing facilities had first been established at the Sime Darby Medical Center (SDMC) in Subang Jaya, thereby increasing local access to EGFR mutation testing to help direct the choice of treatment for advanced lung adenocarcinoma patients. During the study period, SDMC was the only center in Malaysia to perform EGFR mutation testing.
PATIENTS AND METHODS

Patients
Our study population consisted of a convenience sample of Malaysian patients with advanced lung adenocarcinoma, who were being considered for TKI treatment and underwent EGFR testing. Because SDMC was the only institution in the country providing this service between 2009 and 2011, we were able to capture the data of all Malaysian patients who had sent tumor biopsy samples for EGFR mutation testing. Demographic and clinical information of the study population were retrospectively reviewed and analyzed. They included patients from 44 private and public sector hospitals throughout the country.
Tissue samples were obtained from patients in accordance with each center's procedures, either by bronchoscopy, or computed tomography-guided transthoracic needle biopsy to process into formalin-fixed paraffin embedded (FFPE) blocks. Patients from whom tissue samples were not obtained could not have the EGFR status determined, and were excluded. Every attempt was made to secure a tissue diagnosis. When a core biopsy was not possible, cytospin samples of malignant effusions were used to make cell blocks, from which material was obtained for EGFR testing.
Never-smokers were those who smoked less than 100 cigarettes in their lifetime, former smokers were those who had quit smoking more than 1 year ago, and current smokers were those who were still smoking or quit less than 1 year ago.
DNA Extraction
The samples were then sent to SDMC for further examination by a pathologist before being subjected to DNA extraction. Genomic DNA was extracted by a standard procedure from areas of paraffin slides, using the QIAamp DNAFFPE Tissue Kit (QIAGEN GmbH, Munich, Germany) according to the manufacturer's instructions. The quality and quantity of the extracted DNA were determined by nanophotometer (Implen GmbH, Munich, Germany).
Mutational Analysis
Mutation testing was performed by either direct sequencing or real-time polymerase chain reaction (PCR). Bidirectional sequencing 24, 25 was initially used (from November 2009 to August 2011) but the method was later switched to real-time PCR (EGFR RGQ PCR Kit; QIAGEN, Manchester, UK).
The bidirectional sequencing method used primers and PCR conditions as described by Lynch et al. 24 Uncloned PCR fragments were purified and subjected to sequencing before being analyzed for the presence of mutation in both sense and antisense directions.
In real-time-PCR, mutations of EGFR (exons 18, 19, 20, and 21) genes were detected by Amplification Refractory Mutation System primers and Scorpions (Amplification Refractory Mutation System-Scorpion) PCR-based, which was performed using a Rotor-Gene Q (QIAGEN).
All mutation tests were performed at the pathology department of SDMC. All test results were reviewed by a molecular scientist (YKC) and a pathologist (PR), respectively.
Statistical Analysis
Descriptive analysis was performed to provide a profile of the patient population. Variables were summarized by arithmetic means and standard deviation, whereas group categories were expressed in percentages. Differences in mutation rates between groups were examined using the χ 2 test, with statistical significance determined as p less than 0.05.
Logistic regression was performed to determine the patient characteristics (sex, ethnicity, age, and smoking) that predict the presence of EGFR mutation in exon 18, 19, 20, or 21 . Odds ratios (ORs) were calculated using logistic regression to describe the risk of mutation attributed to these characteristics. Model fit was evaluated by Hosmer-Lemeshow goodness-of-fit test, where significance level of á more than 0.05 indicated a well-fitted model. Data analysis was performed using Stata version 11.2 (StataCorp LP, College Station, TX). The study was approved by the Independent Medical Ethics Committee of the SDMC.
RESULTS
Patient Characteristics
The clinical characteristics of the 812 adenocarcinoma patients are described in Table 1 . There were marginally more men among the patients (51%). The patients were predominantly Chinese (63.7%); this was consistent with the higher prevalence of lung cancer among the Chinese in Malaysia. 6 Information on smoking status was available for only 211 patients (26%). Among patients with smoking status information, the majority were never-smokers (58.8%). The direct sequencing method was used for EGFR mutation detection in slightly more than half of the patients (51.2%).
EGFR Mutations in 812 Patients
As shown in Table 1 , among the overall study population, EGFR mutations were detected in the tumors of 321 patients (39.5%). The most common mutation was in exon 19 (23.5%), followed by mutation in exon 21 (14.9%). Very few patients had tumors with mutations in exon 18 (0.6%) and in exon 20 (2.0%). The mean and median ages of patients in the study were 58.9 and 59 years, respectively. When compared on the basis of mutation, the median ages were 59 years among patients with mutation in exon 18 (range, 44-77 years), 56 years for exon 19 (range, 27-83 years), 65 years for exon 20 (range, 30-77 years), and 62 years for exon 21 (range, 30-92 years).
There were 11 instances of tumors with more than one mutation (1.35%). Table 2 shows the comparison of clinical characteristics of patients with EGFR-mutated tumors and those with EGFR-mutation-negative or wild-type tumors. There was no significant difference in the mean age of patients with EGFRmutated tumors and those with EGFR wild-type tumors (58.6 versus 59.1, p = 0.636). There were higher rates of mutation among ethnic Chinese patients (40.8%) compared with Indian (33.3%) and Malay (37.2%) patients. However, the difference was not statistically significant (p = 0.591). A higher percentage of patients had mutations detected by RT-PCR than by direct sequencing, although this was not statistically significant (42.9% versus 36.3%, p = 0.053). Mutations occurred more frequently in women as compared with men (52.5% versus 27.8%, p < 0.001). Mutations in exon 19 (64.6% versus 35.1%, p < 0.001) and exon 21 (63.6% versus 36.4%, p < 0.001) were significantly more common in female than male patients (Table 3) .
EGFR Mutations in 211 Patients with Known Smoking Status
A subanalysis was also performed, comparing the clinical characteristics of patients with EGFR-mutated tumors and those with EGFR wild-type tumors in 211 patients with known smoking status, as shown in Table 4 . The findings of the subgroup analysis were similar to those of the main group analysis. There was no significant difference in the mean age of patients with EGFR-mutated tumors and those with EGFR wild-type tumors (57.5 years versus 60.3 years, p = 0.088). Mutations were more frequently detected in women compared with men (54.3% versus 27.4%, p < 0.001), and in neversmokers compared with ever-smokers (54.8% versus 20.7%, p < 0.001). Table 5 describes the results of multiple logistic regression. Model 1 estimated the odds of mutation among patients with available smoking status data against the four predictive factors of age, sex, smoking status, and ethnicity. Of the 211 patients with smoking data, two patients from other ethnicities were excluded from analysis because of insufficient variation in the outcome variable. The model estimated that women (OR = 1.33), never-smokers (OR = 3.82), and patients of Indian descent (OR = 1.14) had higher odds of mutation, whereas patients aged more than 60 years (OR = 0.79) and Malays (OR = 0.66) had lower odds of mutation. However, only the OR of never-smokers was statistically significant (p = 0.002).
Predictive Factors
Because of the large proportion of patients with missing smoking status data (74%) and the high degree of correlation between smoking and sex of the patient (÷ 2 = 108.8, p < 0.001), a second model was formulated by excluding smoking status as a risk factor. Model 2 used data from all 812 patients to estimate the odds of mutation against the three risk factors of age, sex, and ethnicity. It was found that women had significantly higher odds of mutation (OR = 2.76, p < 0.001). Meanwhile, older patients aged more than 60 years (OR = 0.92), Malay patients (OR = 0.91), and Indian patients (OR = 0.72) tended toward lower odds of mutation. However, these were not statistically significant. Both models were shown to be well-fitted as evaluated by Hosmer-Lemeshow goodnessof-fit test statistic exceeding α more than 0.05.
DISCUSSION
We find the distribution of the four main mutations in the EGFR gene from the current study to be comparable with findings by others, with the overwhelming majority of mutations found in exons 19 and 21.
26,27
Genetic Factors
The association between ethnicity, sex, smoking status, and higher rates of EGFR mutation has been widely repor ted. 1, 17, 19, 22, [28] [29] [30] In our study, the highest rate of EGFR mutation was observed in Chinese patients (41.2%) followed by Indian (35.9%) and Malay patients (37.2%). However, the differences between these ethnic groups were not statistically significant.
As shown in Table 6 , studies from other countries seem to indicate a variation in EGFR mutation distribution among different ethnicities. Asians seem to have a higher occurrence of the mutation than their Western counterparts, the highest reported being in Taiwan (55%). 21 With an overall frequency of 39.9%, the mutation rate found in this study is similar to findings from Korea, China, Japan, Taiwan, India, and Singapore (Table 6 ). Genetic factors have been widely postulated as the possible reason for the different mutation rates internationally. 13, 14, 30 However, it seems that the high rate of mutation seems to occur not only among people of East Asian ethnic descent, but also among Indians from India (44%), and based on our study, Malaysian Indians (35.9%), and Malays (37.2%). Although the genetic relationship of various races and nationalities is complex, some similarities between the East Asians and other Asian races from different countries can be expected.
31,32
Association with Sex and Smoking
Previous studies have shown that an important environmental factor associated with higher rates of EGFR mutations is a never smoking status. 18, 28 On smoking and sex, our study demonstrates similar findings among Malaysians as in other populations. Higher rates of EGFR mutations were found in women compared with men (52.5% versus 27.8%, p < 0.001) and in never-smokers compared with ever-smokers (54.8% versus 20.7%, p < 0.001), as shown in Tables 2 and 4 . An earlier study in Malaysian advanced lung adenocarcinoma patients with unknown EGFR mutation status reported that the response rate to gefitinib was higher in women and neversmokers compared with men and ever-smokers. 33 This is not surprising because these demographic characteristics are associated with an increased likelihood of EGFR mutation positivity. From the results of the two models that we generated, it seems that never-smokers and women are both more likely to be associated with EGFR mutation positivity. We believe the smaller sample (n = 211) used in our first model contributed to the lack of significance for women, despite the higher (OR = 1.33). For this reason, women were found to be significantly correlated with EGFR positivity in the second model. Whereas, because of the lack of smoking data in the second model, which had a larger sample (n = 812), we were not able to generate results for smoking.
In Malaysian society, it can be argued that there exists a confounding association between sex and smoking, with fewer women being smokers than men. Thus, aside from sample size considerations, the confounding relationship between smoking and sex may have been another reason that female patients did not show significance in our first model, whereas it was significant in the second model. In the subgroup of patients with information on smoking, a never-smoking status was independently associated with EGFR mutation positivity (Table 4) .
Consistent with findings from studies elsewhere, EGFR mutations in this study were more common in neversmokers compared with former and current smokers. 1, 15 This occurrence is in contrast with incidences of other mutations in lung cancer, such as mutations of the tumor protein p53 (TP53) gene, 34 KRAS gene, 35 or the deletions of the short arm of chromosome 3, 36 which are more frequently found in patients who smoke. This suggests that EGFR mutations could be caused by carcinogens other than those contained in tobacco smoke. 19 Human papillomavirus type 16 or 18 infections 37 or cooking oil fumes 38 have been implicated as causes of lung cancer in nonsmoking women. Thus, these observations may suggest some association with preferential occurrence of EGFR mutations in nonsmoking women.
Strengths and Limitations
The authors recognize the limitations inherent in this retrospective observational study using the available data from a convenient sample. With this in mind, we would caution that the results may not represent the true prevalence of EGFR mutation in the lung adenocarcinoma population in Malaysia. However, because there is no national study on this topic as yet, our results may be a useful indication of prevalence. Our patients with advanced-stage adenocarcinoma, who were tested for EGFR mutation, represented real-life practice where EGFR TKIs are indicated in the management of advancedstage disease, which is EGFR mutation-positive, and not all stages of the disease. Furthermore, our results are probably reflective of the prevalence of EGFR mutation in Malaysian patients with advanced lung adenocarcinoma.
It is of great interest that we did not find any significant difference in the prevalence of EGFR mutation between the Chinese and the Malays. This is the first report on the prevalence of EGFR mutation in the Malays. The high proportion of Chinese patients was reflective of the higher incidence of lung cancer among the Chinese than the other ethnic groups in Malaysia, where the age-standardized incidence rate for the Chinese is more than twice that of Malays and Indians for both sexes. 8 This study used more than one testing method (direct sequencing and real-time PCR), and the results suggest that real-time PCR was more sensitive than direct sequencing in detecting EGFR mutations. We do not draw definitive conclusions on this finding because this was an observational study, and not designed to compare the two methods. This could be considered another limitation of our study.
The lack of information on the smoking status of a large proportion of patients presented a challenge to the multiple logistic regression analysis presented in this study. Because of this limitation, we presented two logistic regression models to better understand the separate effects of smoking and sex, individually.
However, the strengths of our study include the large sample size and the substantial number of patients from various ethnic groups, despite the rather small sample of ethnic Indian patients. These results were from a single center, which was the only center in Malaysia performing EGFR mutation testing during the period of the study, thus capturing all Malaysian patients diagnosed with advanced lung adenocarcinoma who underwent the test. Furthermore, the use of data from a single testing center and review by a single pathologist minimized the risk of inter-rater bias in the determination of mutation status.
Implications for Clinical Practice
Because patients with EGFR mutations respond better to treatment using TKIs, 2-4 the high percentage of patients found to have EGFR mutations in this study has important clinical implications. Testing for mutation in advanced-stage lung adenocarcinoma should be performed for all patients who are eligible for systemic treatment, regardless of age, sex, ethnicity, and smoking status, and should form part of the molecular pathology diagnosis report. The turnaround time for EGFR testing can be an impediment to smooth decision making. The availability of the results of EGFR mutation testing would help identify the appropriate treatment strategy, especially when time is of the essence for this group of patients. The time gap, between a request for the test until the time EGFR mutation is reported and the treatment initiated, could be related to internal processes between laboratories within institutions. 39 Thus, we support the recommendation by the Asian pathologists and clinicians advisory board published in 2011, 39 which says that reflex testing for EGFR mutation should be performed upon a pathological diagnosis of adenocarcinoma. Such a process would reduce the turnaround time from diagnosis to treatment. This has not yet been established as routine practice in Malaysia, and should become a practice here as well as in other countries in a similar situation.
Aside from clinical considerations, cost-effectiveness should also be considered. As demonstrated by a study from neighbouring Singapore, the availability of mutation status data from routine testing may guide therapy to improve clinical outcomes and at the same time reduce costs. This study considered treatment with TKIs as first-line compared with its use as second-line treatment after cytotoxic chemotherapy in cases of EGFR-positive advanced lung adenocarcinoma. The study also found that first-line TKIs is cost-effective when adopted in cases of EGFR-positive advanced lung adenocarcinoma, compared with TKIs as second-line treatment. 40 In conclusion, this study is the first to include a multiethnic population in South East Asia. Despite the limitations, the results indicate that the frequency of EGFR mutation in this sample of Malaysian lung adenocarcinoma patients is similar to those previously reported in other East Asian countries, such as Korea, China, Japan, and Taiwan. Mutation rates are slightly higher in ethnic Chinese Malaysians, but overall rates did not significantly differ among ethnic Chinese, Malay, or Indian Malaysians. More information is needed about the mutation rate among Malaysian Indians. Similar to other studies, we also found mutations more common in women and never-smokers. From the clinical perspective, these findings point to the need for reflex EGFR mutation testing to be incorporated into the routine practice for advanced lung adenocarcinoma patients. This would ensure faster turnaround time from diagnosis to decision making about the most appropriate treatment strategy, which would be in the best interest of the patients.
